Cancer Advances Announces Allowance of a New Divisional Patent for Monoclonal Antibodies to Progastrin

Cancer Advances, Inc. (Cancer Advances), a wholly owned, biotechnology portfolio company of Cato BioVentures, announces the allowance of a new U.S. divisional patent for monoclonal antibodies to progastrin.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
Cancer Advances Inc.

Cancer Advances

We are excited about our current achievements in gastrointestinal cancer research and development. Our outlook remains positive for future developments in this area of study.

Durham, NC (PRWEB) April 29, 2014

Cancer Advances, Inc. (Cancer Advances), a wholly owned, biotechnology portfolio company of Cato BioVentures, announces the allowance of a new U.S. divisional patent for monoclonal antibodies to progastrin.

Cancer Advances has developed an intellectual property portfolio that currently holds over 100 United States and worldwide patents related to a lead compound, Polyclonal Antibody Stimulator (PAS) that has been clinically studied in three gastrointestinal cancers. PAS is an active immunotherapeutic that induces antibodies against the hormone, gastrin 17 (G17), and its precursor, (gly)G17, of which there is extensive published evidence for a central role of both of these endogenous compounds in the development and progression of gastrointestinal tumors, as well as other tumors.

With the issuance of the allowed patents Cancer Advances will have exclusive rights to use a group of high specificity monoclonal antibodies against progastrin for the treatment ulcers and cancers. Progastrin is the unprocessed precursor to the gastrin hormone. Treatment with these monoclonal antibodies could lead to reduction in the amount of gastrin signaling in patients, thereby reducing the effect gastrin has on their disease. This patent represents a step forward in Cancer Advances’ mission to fight gastrin promoted disease using immunological methods.

“We are excited about our current achievements in gastrointestinal cancer research and development. Our outlook remains positive for future developments in this area of study. We aim to make a worldwide, positive impact with this patent and others as we progress in the fight against gastrin-related diseases,” says Lynda Sutton, president of Cancer Advances.

For more information, please contact:
Lynda Sutton
President, Cancer Advances
lsutton(at)cato(dot)com
919-361-2162
http://www.canceradvancesinc.com
.
About Cancer Advances
Cancer Advances is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.

Please visit our product page for more information on what is in development: http://www.canceradvancesinc.com/product.html.

# # #


Contact

  • Jessica Bliven
    Cato Research
    9197681230
    Email
Follow us on: Contact's Google Plus

Attachments

Cancer Advances Announces Allowance of a New Divisional Patent for Monoclonal Antibodies to Progastrin Cancer Advances Announces Allowance of a New Divisional Patent for Monoclonal Antibodies to Progastrin

Cancer Advances Announces Allowance of a New Divisional Patent for Monoclonal Antibodies to Progastrin